Iris Kennedy, APRN
Nurse Practitioner · Little Rock, ARNPI 1609954148
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Bayer at 31.6% of the total. 2025 is the largest year on record at $6,814, 5.0 times the $1,371 reported in 2021. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 529 payments — averaging $42.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$7K
- Accord Healthcare, Inc.$2K
- Johnson & Johnson$2K
- Sumitomo Pharma America, Inc.$1K
- Myriad Genetic Laboratories, Inc.$1K
- Myovant Sciences Inc.$1K
- plus $7K from 25 others
What the payments were for
- Consulting fees$5,45324%
- Speaking & faculty fees$1,9149%
- Travel & lodging$1,2496%
- Food & beverage$13,16859%
- Education$6063%
- Gifts$830%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 38 | $7,097 |
| Accord Healthcare, Inc. | 22 | $2,454 |
| Johnson & Johnson | 72 | $2,235 |
| Sumitomo Pharma America, Inc. | 63 | $1,383 |
| Myriad Genetic Laboratories, Inc. | 30 | $1,211 |
| Myovant Sciences Inc. | 48 | $1,191 |
| Dendreon Pharmaceuticals LLC | 35 | $1,176 |
| Janssen Scientific Affairs, LLC | 8 | $1,105 |
| Astellas Pharma US Inc | 42 | $1,096 |
| Pfizer | 29 | $537 |
| Novartis | 25 | $477 |
| Verity Pharmaceuticals Inc. | 20 | $371 |
| AbbVie(2 entities) | 21 | $358 |
| Antares Pharma, Inc. | 14 | $260 |
| Rochester Medical Corporation | 11 | $200 |
| Merck | 7 | $182 |
| Blue Earth Diagnostics | 9 | $158 |
| Amgen | 9 | $157 |
| Axonics, Inc. | 3 | $134 |
| Endo Pharmaceuticals Inc. | 1 | $99 |
| Tolmar, Inc. | 4 | $87 |
| Progenics Pharmaceuticals, Inc. | 1 | $78 |
| AstraZeneca | 4 | $69 |
| Urogen Pharma, Inc. | 2 | $68 |
| Teleflex LLC | 1 | $67 |
| Caris MPI, Inc. | 3 | $62 |
| Tempus AI, Inc | 1 | $60 |
| Tolmar Pharmaceuticals, Inc. | 2 | $40 |
| Urovant Sciences Inc | 2 | $28 |
| Procept Biorobotics Corporation | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,473 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 199 | $2,616,783 |
| XtandiEnzalutamide | 147 | $2,075,673 |
| ErleadaApalutamide | 76 | $1,112,729 |
| OrgovyxRelugolix | 227 | $598,622 |
| Abiraterone Acetate | 86 | $146,658 |
| GemtesaVibegron | 81 | $54,569 |
| MyrbetriqMirabegron | 26 | $19,563 |
| Tamsulosin Hcl | 373 | $5,341 |
| Testosterone | 35 | $5,031 |
| Testosterone Cypionate | 95 | $2,999 |
| Trospium Chloride | 30 | $2,192 |
| Imipramine Hcl | 37 | $1,027 |
| Finasteride | 102 | $937 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 58 | $733 |
| Bicalutamide | 32 | $611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $7,097 | $2,616,783199 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $1,096 | $2,095,236173 claims |
| Johnson & JohnsonErleada | $2,235 | $1,112,72976 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $1,383 | $653,191308 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,105 | $146,65886 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Little Rock
- Julia PonderLittle Rock$21K
- Olivia CoxLittle Rock$14K
- Sarah AtkinsLittle Rock$12K
- Lauren ByersLittle Rock$8K
- Suzanne BroadwayLittle Rock$6K
- Natalie ByarsLittle Rock$6K
- Kristie CronkhiteLittle Rock$5K
- Mary GuellLittle Rock$5K
- Danielle LeeperLittle Rock$4K
- Leigh JohnsonLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.